Novo Nordisk to Acquire Dicerna for ~$3.3B
Shots: Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a […]
Shots: Novo Nordisk to acquire all outstanding shares of Dicerna common stock for $38.25/share in cash making a total equity value of ~$3.3B representing a […]
Shots: AcelRx signs a merger agreement to acquire Lowell for $32.5M in cash and an additional ~$26.0M in contingent consideration upon the achievement of regulatory […]
Shots: Organon to acquire Forendo for a total consideration of $954M including $75M up front, $9M in Forendo debt, $270M upon the achievement of development […]
Shots: Coloplast to acquire Atos Medical for an enterprise value of $2.49B from PAI Partners. The transaction is expected to close in Q2’22 Coloplast obtains […]
Shots: Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in […]
Shots: Codiak to receive $65M of in-kind manufacturing services for its clinical-stage programs and hold its pipeline of therapeutic candidates along with exosome engineering and […]
Shots: Takeda is eligible to receive $10M up front in addition to $35M in Calithera Series A preferred stock and is eligible to receive clinical […]
Shots: Hologic to acquire Bolder Surgical for ~$160M which is a provider of advanced energy vessel sealing surgical devices. The acquisition is expected to be closed by […]
Shots: Pacira Signs a definitive agreement to acquire Flexion for $8.50/share in cash along with one non-tradeable CVR of ~$8.00/share in cash upon the achievement […]
Shots: Supernus signs a definitive agreement to acquire Adamas for $8.10/ share in cash (~$400M) & 2 non-tradable CVR of ~$1.00 00/share in cash (~$50M) […]
Shots: Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22 The acquisition […]
Shots: Inotiv to acquire Plato BioPharma for $15.0M that consist of $10.0M in cash, $2.0M in Inotiv’s common shares (57,587) based on the average closing […]
Shots: Merck to acquire Acceleron for $180/share in cash making a total equity value of ~$11.5B representing a premium of 2.6% to the stock’s closing […]
Shots: Alexion has exercised its option to acquire all remaining equity in Caelum for CAEL-101 which is currently being evaluated in P-III CARES clinical program […]
Shots: The acquisition includes upfront, milestones, and other consideration payments. Abexxa will continue to operate in the Arlington The acquisition will allow Boehringer to access […]
Shots: Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & […]
Shots: ZOLL Medical to acquire all outstanding ordinary shares of Itamar Medical for $31/ADS or $1.03/ordinary share in cash making a total deal value of […]
Shots: Smiths to receive 2.5M at closing in cash and stock which is currently valued at ~$500M, $1.85B in cash along with liabilities & is […]
Shots: Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing […]
Shots: Advent and GIC to acquire Sobi for ~$8B (SEK 69.4B) at $27.33/share (SEK 235) representing a premium of 34.5% to the closing price of […]
Shots: Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s […]
Shots: Baxter in talks to acquire Hill-Rom for ~$10B with $150/ share representing a premium of 13% to the stock’s closing price of $132.90. The […]
Shorts: Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the […]
Shots: The acquisition will bolster Verily’s clinical trial system and Baseline platform to improve the efficiency, costs in clinical trials & speed up it at […]
Shots: Amgen to acquire all outstanding shares of Teneobio for $900M as up front and $1.6B in cash as contingent milestones to Teneobio equity holders. […]
Shots: Eli Lilly to acquire Protomer Technologies for ~$1B, with the achievement of future development and commercial milestones Earlier, Lilly led an equity investment in […]
Shots: Prothena is eligible to receive ~$1.2B as development and commercial milestones including $100M as up front and near-term clinical milestones Novo Nordisk acquires Prothena’s […]
Shots: PerkinElmer to acquire IDS in all cash transactions for ~$155M. The transaction is expected to be completed in Q3’21 The acquisition will allow PerkinElmer […]
Shots: Kuur will receive $70M up front primarily in Athenex common stock and is eligible to receive ~$115 M as a milestone at Athenex’s sole […]
Shots: Avantor to acquire Ritter and its affiliates in an all-cash transaction with an up front equity purchase price of ~ $1.06B along with additional […]
Shots: DiaSorin to acquire Luminex for $37.00/ share in an all-cash transaction, with 23% premium based on closing stock price of Luminex on 24 Feb, […]
Shots: Microsoft to acquire all outstanding shares of Nuance for $56.00/ share, making a total deal value of $19.7B in cash with a premium of […]
Shots: Sanofi to acquire Tidal Therapeutics for $160M up front and ~ $310M following the achievement of certain milestones The acquisition will add Tidal’s innovative […]
Shots: Hologic to acquire Mobidiag for ~$795M which includes ~$714M in cash for Mobidiag’s equity and debt of $81M. The acquisition is expected to close […]
Shots: ACEA to receive up to ~$38M in shares of Sorrento common stock, $450M as additional payments upon the achievement of clinical & sales milestones […]
Shots: Immunai acquires the Dropprint Genomics and also expand its team with the hiring of new experts in immunology, single-cell technologies and machine learning The […]
Shots: Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost […]
Shots: Takeda exercised its option to acquire Maverick for up to $525M up front as well as development and regulatory milestones including Takeda’s current equity […]
Shots: Resolution to receive $550M in cash at closing and ~$145M following the achievement of certain milestones. The transaction is expected to close in Apr’2021 […]
Shots: Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The […]
Shots: Boston Scientific to acquire the global surgical business of Lumenis for $1.07B as an up front in cash. The transaction is expected to be […]
Shots: Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial […]
Shots: Mitokinin to receive an up front and will continue to develop its PINK1 activator program through completion of IND enabling studies for its lead […]
Shots: Hologic to acquire Diagenode for ~$159M. The transaction will expand and diversifies Hologic’s diagnostic business across test menu, customer segments and geography The acquisition […]
Shots: Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for […]
Shots: Merck to acquire all outstanding share of Pandion for $60/share in cash, representing the equity value of ~$1.85B. The transaction is expected to close […]
Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK […]
Shots: Jazz to acquire GW Pharmaceuticals for $220/ GW ADS, out of which $200 in cash and $20 in Jazz ordinary shares, making a total […]
Shots: Horizon to acquire Viela Bio for $53/ share, representing an equity value of $3.05B with a 53% premium over a closing price to Viela’s […]
Shots: Boston Scientific to acquire Preventice for ~$1.2B including $925M as up front, up to an additional $300M as commercial milestones. However, Boston Scientific has […]
Shots: Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to […]
Shots: Thermo Fisher acquires Mesa Biotech for $450M in cash. Mesa Biotech will receive an additional ~$100M in cash on the completion of milestones while […]
Shots: Philips to acquire Capsule technologies for $635M in cash. The transaction is expected to be completed in H1’21 with the addition of ~300 employees […]
Shots: Sanofi to acquire Kymab for $1.1B up front and ~$350M following the achievement of certain milestones. The transaction is expected to be completed in […]
Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies Sarepta […]
Shots: PerkinElmer to acquire Oxford Immunotec for $22/ share with a premium of ~28.3% to the closing price/ share of $17.15 on Jan 5, 2021, […]
Shots: Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021 The acquisition will […]
Shots: Hologic acquired Somatex Medical Technologies for ~$64M. The acquisition of Somatex’s differentiated products will enable Hologic to strengthen & expand its breast marker portfolio […]
Shots: Novartis to acquire all outstanding shares of Cadent for a total value of ~$770M. Cadent to receive $210M up front and is eligible for […]
Shots: Lilly to acquire Prevail for $22.50/ share in cash (~ $880M) payable at closing plus one non-tradable CVR worth up to $4.00/ share in […]
Shots: Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide) […]
Shots: Grünenthal to acquire EU rights (Ex- Spain and the UK) of Crestor & its associated brands for ~$350M and will take over bulk production […]
Shots: Dr. Reddy to acquire Glenmark’s brands Momat Rino (for Russia, Kazakhstan, and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan & Uzbekistan), […]
Shots: Selvita to acquire 100% of the outstanding shares in Fidelta for $37.08M + customary adjustments for net cash & working capital The acquisition will […]
Shots: Merck to acquire all outstanding shares of Oncolmmune for $425 M in cash as an upfront. Additionally, Oncolmmune will receive sales-based and contingent payments […]
Shots: Novo Nordisk to acquire all outstanding shares of Emisphere for $1.35B and also acquires royalty stream obligations to the firm’s biggest shareholder (MHR) for […]
Shots: Merck will acquire all the outstanding shares of VelosBio for $2.75B in cash. The transaction is expected to be closed by the end of […]
Shots: Sanofi to acquire all outstanding shares of Kiadis for $6.34/ share, representing an equity value of $358.76M. The offer price represents a premium of […]
Shots: Vedere Bio received $150M as upfront payments and is eligible to receive up to $130M as milestones making a total deal value of $280M. […]
Shots: Exact Sciences to acquire Thrive in all cash & stock transaction for ~2.15B out of which $1.7B would be payable at closing, consisting of […]
Shots: Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is […]
Shots: Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B The […]
Shots: BMS to acquire all the outstanding shares of MyoKardia’s common stock for $225.00/ share in cash, making a total deal value of ~$13.1B. The […]
Shots: Philips will acquire Intact Vascular for $275M up front and deferred payments of $85M upon completion of the transaction. The transaction is expected to […]
Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected […]
Shots: J&J acquires Momenta in all-cash transaction at a price of $52.50/ share, making a total deal value as $6.5B. The transaction is expected to […]
Shots: Sanofi to acquire Principia Biopharma in an all-stock transaction, at $100/share making total deal value ~$3.68B in cash. The transaction is expected to be […]
Shots: The acquisition will expand Medtronic’s capabilities to serve people using multiple daily injections (MDI) to manage diabetes with the addition of Companion Medical’s InPen […]
Shots: Ligand to acquire all outstanding shares of Pfenex for $12/share in cash or $438 million in equity value with a 57% premium to the […]
Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The […]
Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection […]
Shots: Siemens Healthineers to acquire Varian in an all-cash transaction, at a price of $177.50/ share with 42% to the 30-day volume-weighted average closing price […]
Shots: Sorrento enters into letter of intent to acquire SmartPharm and develops pipeline of gene-encoded therapeutic Ab, initiating with Sorrento’s STI-1499 or COVI-GUARD, currently preclinical […]
Shots: Gilead invests $300M to obtain 49.9% equity interest in Tizona and receives an exclusive option to acquire remaining stakes of Tizona for up to […]
Shots: GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five […]
Shots: Under the amended agreement, the offer price increased from $44.5 to $49/QIAGEN share in cash, representing a premium of 35% to the closing price […]
Shots: Gilead to receive an up front in cash and convertible notes into Kronos equity, regulatory & commercial milestones along with royalties on sales of […]
Copyright © 2024 | WordPress Theme by MH Themes